Clinical management of BRCA1 and BRCA2 mutation carriers

Nature Clinical Practice Oncology

Volumn 3, Issue 1, 2006, Pages 2-3

  Domchek, Susan M ^a   Armstrong, Katrina ^a   Weber, Barbara L ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PLATINUM DERIVATIVE; PROGESTERONE; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; DRUG SENSITIVITY; ECHOMAMMOGRAPHY; FAMILIAL CANCER; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HETEROZYGOTE; HORMONE SUBSTITUTION; HUMAN; MASTECTOMY; MENOPAUSE; NONHUMAN; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK REDUCTION; TRANSVAGINAL ECHOGRAPHY;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; OVARIECTOMY;

EID: 30944448279     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0384     Document Type: Review

References (13)

1. Rebbeck TR et al. (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346: 1616-1622
2. Kauff ND et al. (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346: 1609-1615
3. Narod SA et al. (1998) Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 339: 424-428
4. Narod SA et al. (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94: 1773-1779
5. Rebbeck TR et al. (2005) Effect of short term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 23: 7804-7810
6. Anderson GL et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712
7. Meijers-Heijboer H et al. (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345: 159-164
8. Narod SA et al. (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Lancet 356: 1876-1881
9. King MC et al. (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286: 2251-2256
10. Warner E et al. (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292: 1317-1325
11. Pierce LJ et al. (2000) Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18: 3360-3369
12. Schwartz MD et al. (2004) Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 22: 1823-1829
13. Farmer H et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921